NorthStrive Biosciences engages Charles River for probiotic CRO work
NorthStrive Biosciences, a subsidiary of Nasdaq-listed PMGC Holdings (ELAB), has engaged Charles River Laboratories to conduct analytical characterisation work on its two lead engineered probiotic candidates, EL-22 and EL-32. The statement of work, executed in late September 2026, covers DNA isolation, preparation and gene copy-number analysis using nucleic-acid amplification and fluorescent-probe technology, with testing to be carried out at Charles River's US Biologics Testing facilities.
The focus of the work is plasmid copy number, a foundational quality attribute for any genetically engineered bacterial product. Establishing reliable, quantitative methods for this parameter is an early but necessary step in building the chemistry, manufacturing and controls (CMC) package that regulators expect ahead of an IND submission. NorthStrive said the data will support product identity, manufacturing consistency and comparability against previously manufactured batches.
The platform and its target market
EL-22 and EL-32 are being developed to address muscle preservation, with a particular focus on patients using GLP-1 receptor agonists for weight loss. That is a commercially topical positioning: the rapid uptake of semaglutide and tirzepatide has created clinical concern about the proportion of weight lost as lean mass rather than fat, opening a potential adjunct-therapy niche that several biotechs and nutrition-science companies are now targeting.
Tara Lehner, Head of Development at NorthStrive Biosciences, said the engagement would "give us quantitative analytical data around plasmid copy number and contribute to the broader characterisation package we are building for EL-22 and EL-32." She framed the work as transforming an innovative platform into "a reproducible and ultimately scalable pharmaceutical product."
Competitive and regulatory context
Engineered probiotics as a drug delivery modality sit at the intersection of synthetic biology and biologics development, and the regulatory path for such products is still being defined by agencies including the FDA and EMA. Unlike conventional live biotherapeutic products (LBPs), which are already subject to dedicated FDA guidance, genetically engineered bacterial candidates face additional scrutiny around containment, genetic stability and ecological risk, all of which make early analytical rigour particularly important.
The broader LBP and engineered microbiome space has attracted meaningful investment over the past several years, with a number of companies advancing candidates through early clinical stages. NorthStrive is at a pre-IND stage, meaning the Charles River engagement is preliminary analytical groundwork rather than a pivotal study. PMGC Holdings, the parent entity, describes itself as a diversified holding company, and NorthStrive is one of several subsidiaries operating across different sectors. That structure is worth noting when assessing the depth of resource behind the programme.
Charles River Laboratories is one of the largest global contract research organisations by revenue, providing discovery, development and manufacturing support to pharmaceutical and biotech clients worldwide. Its US Biologics Testing division has experience across a wide range of biologic modalities, giving NorthStrive access to infrastructure that would be difficult to replicate in-house at this stage of company development.
The company has not disclosed a target IND submission date, and no clinical data for EL-22 or EL-32 have been released. Near-term milestones to watch will include completion of the plasmid copy-number study, publication of any preclinical efficacy data, and formal designation of the lead indication and regulatory pathway.